The protective effects of plasma gelsolin on stroke outcome in rats

Huong T. Le, Aaron C. Hirko, Jeffrey S. Thinschmidt, Maria Grant, Zhimin Li, Joanna Peris, Michael A. King, Jeffrey A. Hughes, Sihong Song

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background: To date, recombinant tissue plasminogen activator (rtPA) is the only approved drug for ischemic stroke. It is intravenously administered functioning as a thrombolytic agent and is used to obtain reperfusion of the affected area of the brain. Excitotoxicity, inflammation and apoptosis are all involved in delayed neuronal death following stroke and offer multiple opportunities to intervene with neuroprotective agents. Gelsolin (GSN) is an actin- and calcium-binding protein mediating the disassembly of actin filaments and activity of calcium channels. It also functions as a regulator of apoptosis and inflammatory responses. This study tests the hypothesis that increasing the concentration of the form of GSN known as plasma GSN (pGSN) near an infarct will provide neuroprotection following ischemic stroke.Methods: We induced middle cerebral artery occlusion (MCAO) in male rats via intracranial injection of endothelin-1 (ET-1), a potent vasoconstrictor, and then treated with local delivery of pGSN. Whole brain laser Doppler perfusion imaging was performed through the skull to assess MCAO effectiveness. Cylinder and vibrissae tests evaluated sensorimotor function before and 72 h after MCAO. Infarct volumes were examined 72 h after MCAO via 2, 3, 5-triphenyltetrazolium chloride (TTC) assay.Results: Estimates of relative cerebral perfusion were significantly decreased in all groups receiving MCAO with no differences detected between treatments. Despite equivalent initial strokes, the infarct volume of the pGSN treatment group was significantly reduced compared with the untreated MCAO rats at 72 h. ET-1 induced significant deficits in both cylinder and vibrissae tests while pGSN significantly limited these deficits.Conclusion: Gelsolin could be a promising drug for protection against neurodegeneration following ischemic stroke.

Original languageEnglish (US)
Article number13
JournalExperimental and Translational Stroke Medicine
Volume3
Issue number1
DOIs
StatePublished - Nov 2 2011
Externally publishedYes

Fingerprint

Gelsolin
Middle Cerebral Artery Infarction
Stroke
Vibrissae
Endothelin-1
Microfilament Proteins
Calcium-Binding Proteins
Perfusion Imaging
Fibrinolytic Agents
Brain
Neuroprotective Agents
Vasoconstrictor Agents
Tissue Plasminogen Activator
Calcium Channels
Actin Cytoskeleton
Skull
Pharmaceutical Preparations
Stroke Volume
Reperfusion
Lasers

Keywords

  • Endothelin-1 induced mcao
  • Ischemic stroke
  • Plasma gelsolin
  • Protective effect

ASJC Scopus subject areas

  • Neuroscience (miscellaneous)
  • Cognitive Neuroscience

Cite this

Le, H. T., Hirko, A. C., Thinschmidt, J. S., Grant, M., Li, Z., Peris, J., ... Song, S. (2011). The protective effects of plasma gelsolin on stroke outcome in rats. Experimental and Translational Stroke Medicine, 3(1), [13]. https://doi.org/10.1186/2040-7378-3-13

The protective effects of plasma gelsolin on stroke outcome in rats. / Le, Huong T.; Hirko, Aaron C.; Thinschmidt, Jeffrey S.; Grant, Maria; Li, Zhimin; Peris, Joanna; King, Michael A.; Hughes, Jeffrey A.; Song, Sihong.

In: Experimental and Translational Stroke Medicine, Vol. 3, No. 1, 13, 02.11.2011.

Research output: Contribution to journalArticle

Le, HT, Hirko, AC, Thinschmidt, JS, Grant, M, Li, Z, Peris, J, King, MA, Hughes, JA & Song, S 2011, 'The protective effects of plasma gelsolin on stroke outcome in rats', Experimental and Translational Stroke Medicine, vol. 3, no. 1, 13. https://doi.org/10.1186/2040-7378-3-13
Le, Huong T. ; Hirko, Aaron C. ; Thinschmidt, Jeffrey S. ; Grant, Maria ; Li, Zhimin ; Peris, Joanna ; King, Michael A. ; Hughes, Jeffrey A. ; Song, Sihong. / The protective effects of plasma gelsolin on stroke outcome in rats. In: Experimental and Translational Stroke Medicine. 2011 ; Vol. 3, No. 1.
@article{8fd0d21b265b4e63ab1bfc2bfe68dbc0,
title = "The protective effects of plasma gelsolin on stroke outcome in rats",
abstract = "Background: To date, recombinant tissue plasminogen activator (rtPA) is the only approved drug for ischemic stroke. It is intravenously administered functioning as a thrombolytic agent and is used to obtain reperfusion of the affected area of the brain. Excitotoxicity, inflammation and apoptosis are all involved in delayed neuronal death following stroke and offer multiple opportunities to intervene with neuroprotective agents. Gelsolin (GSN) is an actin- and calcium-binding protein mediating the disassembly of actin filaments and activity of calcium channels. It also functions as a regulator of apoptosis and inflammatory responses. This study tests the hypothesis that increasing the concentration of the form of GSN known as plasma GSN (pGSN) near an infarct will provide neuroprotection following ischemic stroke.Methods: We induced middle cerebral artery occlusion (MCAO) in male rats via intracranial injection of endothelin-1 (ET-1), a potent vasoconstrictor, and then treated with local delivery of pGSN. Whole brain laser Doppler perfusion imaging was performed through the skull to assess MCAO effectiveness. Cylinder and vibrissae tests evaluated sensorimotor function before and 72 h after MCAO. Infarct volumes were examined 72 h after MCAO via 2, 3, 5-triphenyltetrazolium chloride (TTC) assay.Results: Estimates of relative cerebral perfusion were significantly decreased in all groups receiving MCAO with no differences detected between treatments. Despite equivalent initial strokes, the infarct volume of the pGSN treatment group was significantly reduced compared with the untreated MCAO rats at 72 h. ET-1 induced significant deficits in both cylinder and vibrissae tests while pGSN significantly limited these deficits.Conclusion: Gelsolin could be a promising drug for protection against neurodegeneration following ischemic stroke.",
keywords = "Endothelin-1 induced mcao, Ischemic stroke, Plasma gelsolin, Protective effect",
author = "Le, {Huong T.} and Hirko, {Aaron C.} and Thinschmidt, {Jeffrey S.} and Maria Grant and Zhimin Li and Joanna Peris and King, {Michael A.} and Hughes, {Jeffrey A.} and Sihong Song",
year = "2011",
month = "11",
day = "2",
doi = "10.1186/2040-7378-3-13",
language = "English (US)",
volume = "3",
journal = "Experimental and Translational Stroke Medicine",
issn = "2040-7378",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - The protective effects of plasma gelsolin on stroke outcome in rats

AU - Le, Huong T.

AU - Hirko, Aaron C.

AU - Thinschmidt, Jeffrey S.

AU - Grant, Maria

AU - Li, Zhimin

AU - Peris, Joanna

AU - King, Michael A.

AU - Hughes, Jeffrey A.

AU - Song, Sihong

PY - 2011/11/2

Y1 - 2011/11/2

N2 - Background: To date, recombinant tissue plasminogen activator (rtPA) is the only approved drug for ischemic stroke. It is intravenously administered functioning as a thrombolytic agent and is used to obtain reperfusion of the affected area of the brain. Excitotoxicity, inflammation and apoptosis are all involved in delayed neuronal death following stroke and offer multiple opportunities to intervene with neuroprotective agents. Gelsolin (GSN) is an actin- and calcium-binding protein mediating the disassembly of actin filaments and activity of calcium channels. It also functions as a regulator of apoptosis and inflammatory responses. This study tests the hypothesis that increasing the concentration of the form of GSN known as plasma GSN (pGSN) near an infarct will provide neuroprotection following ischemic stroke.Methods: We induced middle cerebral artery occlusion (MCAO) in male rats via intracranial injection of endothelin-1 (ET-1), a potent vasoconstrictor, and then treated with local delivery of pGSN. Whole brain laser Doppler perfusion imaging was performed through the skull to assess MCAO effectiveness. Cylinder and vibrissae tests evaluated sensorimotor function before and 72 h after MCAO. Infarct volumes were examined 72 h after MCAO via 2, 3, 5-triphenyltetrazolium chloride (TTC) assay.Results: Estimates of relative cerebral perfusion were significantly decreased in all groups receiving MCAO with no differences detected between treatments. Despite equivalent initial strokes, the infarct volume of the pGSN treatment group was significantly reduced compared with the untreated MCAO rats at 72 h. ET-1 induced significant deficits in both cylinder and vibrissae tests while pGSN significantly limited these deficits.Conclusion: Gelsolin could be a promising drug for protection against neurodegeneration following ischemic stroke.

AB - Background: To date, recombinant tissue plasminogen activator (rtPA) is the only approved drug for ischemic stroke. It is intravenously administered functioning as a thrombolytic agent and is used to obtain reperfusion of the affected area of the brain. Excitotoxicity, inflammation and apoptosis are all involved in delayed neuronal death following stroke and offer multiple opportunities to intervene with neuroprotective agents. Gelsolin (GSN) is an actin- and calcium-binding protein mediating the disassembly of actin filaments and activity of calcium channels. It also functions as a regulator of apoptosis and inflammatory responses. This study tests the hypothesis that increasing the concentration of the form of GSN known as plasma GSN (pGSN) near an infarct will provide neuroprotection following ischemic stroke.Methods: We induced middle cerebral artery occlusion (MCAO) in male rats via intracranial injection of endothelin-1 (ET-1), a potent vasoconstrictor, and then treated with local delivery of pGSN. Whole brain laser Doppler perfusion imaging was performed through the skull to assess MCAO effectiveness. Cylinder and vibrissae tests evaluated sensorimotor function before and 72 h after MCAO. Infarct volumes were examined 72 h after MCAO via 2, 3, 5-triphenyltetrazolium chloride (TTC) assay.Results: Estimates of relative cerebral perfusion were significantly decreased in all groups receiving MCAO with no differences detected between treatments. Despite equivalent initial strokes, the infarct volume of the pGSN treatment group was significantly reduced compared with the untreated MCAO rats at 72 h. ET-1 induced significant deficits in both cylinder and vibrissae tests while pGSN significantly limited these deficits.Conclusion: Gelsolin could be a promising drug for protection against neurodegeneration following ischemic stroke.

KW - Endothelin-1 induced mcao

KW - Ischemic stroke

KW - Plasma gelsolin

KW - Protective effect

UR - http://www.scopus.com/inward/record.url?scp=81255138901&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81255138901&partnerID=8YFLogxK

U2 - 10.1186/2040-7378-3-13

DO - 10.1186/2040-7378-3-13

M3 - Article

VL - 3

JO - Experimental and Translational Stroke Medicine

JF - Experimental and Translational Stroke Medicine

SN - 2040-7378

IS - 1

M1 - 13

ER -